APRILE HARRIS: Open Payments
NPI 1831133701 · ELKTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,248 in 46 payments from 19 companies in 2025. Trend: 2023 $788 · 2024 $1,344 · 2025 $1,248
Food & beverage: $1,226Education: $22
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 5 | $275 |
| Calliditas Therapeutics US Inc. | 4 | $215 |
| Fresenius USA Marketing, Inc. | 4 | $105 |
| Amgen Inc. | 5 | $94 |
| Travere Therapeutics, Inc. | 5 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $51 |
| AKEBIA THERAPEUTICS INC | 2 | $43 |
| Novartis Pharmaceuticals Corporation | 2 | $41 |
Products named: TARPEYO, XPHOZAH 30 MG, VELPHORO, TAVNEOS, IBSRELA, JARDIANCE, Vafseo, JYNARQUE.
Industry payments across MD — which companies pay providers there.
